文献速递骨软组织肉瘤与黑色素瘤

可切除III/IV期皮肤黑色素瘤新辅助免疫治疗——瑞典回顾性真实世界研究(NEO-MEL)

Neoadjuvant immunotherapy for patients with resectable stage III/IV cutaneous melanoma - A Swedish retrospective real-world study (NEO-MEL).
PubMed 文献 · Eur J Cancer · 2025-06-01

该研究在瑞典三个学术中心回顾性纳入2022年1月1日至2024年6月30日期间接受新辅助免疫检查点抑制剂治疗的可切除III/IV期皮肤黑色素瘤患者118例,98%接受纳武利尤单抗单药治疗,42%达到主要病理缓解,中位随访12个月时估计12个月无事件生存率为72%(95%CI 63-82),3级及以上免疫相关不良事件发生率为9%。

要点

  • 118例可切除III/IV期皮肤黑色素瘤患者接受新辅助免疫检查点抑制剂,98%为纳武利尤单抗单药。
  • 42%达到主要病理缓解,9%部分病理缓解,31%无病理缓解。
  • 12个月无事件生存率72%(95%CI 63-82),无复发生存率74%(95%CI 65-83);3级及以上免疫相关不良事件9%。

核心结论

  • 在基于人群的常规临床实践中,可切除III/IV期皮肤黑色素瘤患者早期采用新辅助免疫检查点抑制剂治疗是可行的,并提供了与临床试验相似的有利疗效和安全性结局。

研究设计与样本

  • 在瑞典三个学术中心开展的一项基于人群的研究,纳入相应地区2022年1月1日至2024年6月30日期间接受新辅助免疫检查点抑制剂治疗的所有晚期但可切除的皮肤黑色素瘤患者,数据从医疗记录中回顾性收集,共纳入118例患者进行分析。

主要发现

  • 患者接受新辅助免疫检查点抑制剂的中位治疗次数为2次,98%接受纳武利尤单抗单药治疗,88%按计划接受手术。
  • 在所有开始治疗的患者中,42%经历主要病理缓解(MPR),9%部分病理缓解(pPR),31%无病理缓解(pNR)。
  • 在中位随访12个月时,估计12个月无事件生存率为72%(95%CI 63-82),无复发生存率(RFS)为74%(95%CI 65-83)。
  • 估计12个月RFS在MPR患者中为94%,在pPR患者中为91%,在pNR患者中为61%。
  • 9%的患者发生3级及以上免疫相关不良事件。

关键数值与推荐

  • 主要病理缓解(MPR)率为42%,部分病理缓解(pPR)率为9%,无病理缓解(pNR)率为31%。
  • 12个月无事件生存率为72%(95%CI 63-82),12个月无复发生存率为74%(95%CI 65-83)。
  • 12个月无复发生存率:MPR患者94%,pPR患者91%,pNR患者61%。
  • 3级及以上免疫相关不良事件发生率为9%。

临床怎么用

  • 原文结论指出,在基于人群的常规临床实践中,可切除III/IV期皮肤黑色素瘤患者早期采用新辅助免疫检查点抑制剂治疗是可行的,并提供了与临床试验相似的有利疗效和安全性结局。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Recent clinical trials have demonstrated that neoadjuvant administration of PD-1 + /- CTLA-4 inhibitor is superior to adjuvant PD-1 inhibitors in patients with resectable stage III and IV cutaneous melanoma. However, the generalizability of these results to an unselected patient population treated in routine clinical settings remains unclear. METHODS: A population-based study was conducted across three academic centers in Sweden, including all patients with advanced but resectable cutaneous melanoma treated with neoadjuvant ICI in the corresponding regions from January 1, 2022, to June 30, 2024. Data were retrospectively collected from medical records. RESULTS: A total of 118 patients were included in the analysis. Patients received a median of two treatments of neoadjuvant ICI, 98 % received nivolumab monotherapy, and 88 % had surgery as planned. Among all patients who started treatment, 42 % experienced a major pathological response (MPR), 9 % a partial pathological response (pPR), 31 % no pathological response (pNR). At a median follow-up time of 12 months, the estimated 12-month event-free survival was 72 % (95 % CI, 63-82) and the recurrence-free survival (RFS) was 74 % (95 % CI, 65-83). The estimated 12-month RFS was 94 % in patients with an MPR, 91 % among those with a pPR, and 61 % among those with a pNR. Grade ≥ 3 immune-related adverse events occurred in 9 % of the patients. CONCLUSIONS: Early adoption of neoadjuvant ICI therapy in patients with resectable stage III and IV cutaneous melanoma treated in population-based routine clinical practice was feasible and provided beneficial efficacy and safety outcomes, similar to those seen in clinical trials.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Nelson A, Krabbe E, Björkström K, et al. Neoadjuvant immunotherapy for patients with resectable stage III/IV cutaneous melanoma - A Swedish retrospective real-world study (NEO-MEL). Eur J Cancer. 2025. PMID: 40456667. doi:10.1016/j.ejca.2025.115485

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。